Preliminary Program subject to change
Molecular Modeling throughout the Drug Discovery Process II
Presentation Type	Oral
Summary Statement
Presider:	Wendy D. Cornell, Merck & Co., Rahway, NJ
Targeting Protein Kinases in Drug Discovery Beth Lunney, Pfizer Global R&D, La Jolla, CA Design of New AIDS Drugs: A Multi-disciplinary Attack on the Problem of Drug Resistance Kalyan Das1, Arthur D. Clark1, Yulia Volovik Frenkel1, Paul J. Lewi2, Jan Heeres2, Marc R. de Jonge2, Lucien M. H. Koymans2, Paul A.J. Janssen2, Donald W. Ludovici3, Bart De Corte3, Robert W. Kavash3, Chih Y. Ho3, Hong Ye3, Mark. A. Lichtenstein3, Michael J. Kukla3, Rudi Pauwels4, Koen Andries4, Marie-Pierre de Béthune4, Stephen H. Hughes5 and Eddy Arnold6, (1)Center for Advanced Biotechnology and Medicine, and Rutgers University, Piscataway, NJ, (2)Center for Molecular Design, Belgium, (3)Janssen Research Foundation, Spring House, PA, (4)Tibotec, Mechelen, Belgium, (5)HIV Drug Resistance Program, Frederick, (6) Rutgers University, Piscataway, NJ Intermission Cardiac Ion Channel Pharmacology and Structure-Function Analysis Chris Culberson, Merck & Co, Inc, West Point, PA Patenting 3D Structural Information in the Aftermath of the Trilateral Project Alicia Russo, FITZPATRICK, CELLA, HARPER & SCINTO, New York, NY Break Panel Discussion -- Career Opportunities in Drug Discovery Molecular Modeling

General Submissions